Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONAL Stop-Ig domain in haematological malignancy
ACTRN12624000963527Phase 3Recruiting
- Sponsor
- Monash University
- Start
- May 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin, trimethoprim + sulfamethoxazole, doxycycline, amoxicillin + clavulanate, ciprofloxacin and 1 more in hypogammaglobulinemia and hematopoietic malignancies (3 arms), sponsored by Monash University. Primary endpoint: Event-free survival. Started May 2025; status: recruiting.
02
Drugs
polyvalent human immunoglobulintrimethoprim + sulfamethoxazoledoxycyclineamoxicillin + clavulanateciprofloxacin
03
Conditions
hypogammaglobulinemiahematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12624000963527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000963527.